Androgen Receptor Pathway Inhibitors Vs. Docetaxel Chemotherapy for Metastatic Hormone-sensitive and First-line Castration Resistant Prostate Cancer

Overview

Journal World J Urol

Specialty Urology

Date 2024 Dec 28

PMID 39731623

Authors

Mike Wenzel

Benedikt Hoeh

Clara Humke

Cristina Cano Garcia

Carolin Siech

Thomas Steuber

Markus Graefen

Miriam Traumann

Luis Kluth

Felix K H Chun

Philipp Mandel

Affiliations

Soon will be listed here.

Abstract

Purpose: No currently available phase III trial compared docetaxel vs. androgen receptor pathway inhibitors (ARPI) regarding cancer-control outcomes in metastatic hormone-sensitive prostate cancer (mHSPC). Moreover, few is known about the effect of sequential therapies in mHSPC and subsequent metastatic castration resistant prostate cancer (mCRPC).

Methods: We relied on the FRAMCAP database and compared docetaxel vs. ARPI in mHSPC patients regarding time to mCRPC (ttCRPC) and overall survival (OS). Sensitivity analyses addressed high volume mHSPC patients. Finally, sequential therapies were compared regarding progression-free survival (PFS) and OS in first-line mCRPC.

Results: Of 419 included mHSPC patients, 25% received docetaxel vs. 75% ARPI. ARPI patients were significantly older (71 vs. 66 years), and harbored lower baseline PSA (38 vs. 183 ng/ml, both p ≤ 0.002). Median ttCRPC was significantly longer for ARPI than for docetaxel-treated patients (30 vs. 17 months, hazard ratio [HR]: 0.49, p < 0.001). In OS analyses, ARPI patients also exhibited significantly longer OS, relative to docetaxel patients (96 vs. 50 months, HR: 0.67, p = 0.03). After multivariable adjustment in Cox regression models, no difference between both treatments remained in both analyses (all p > 0.05). In sensitivity analyses of high volume mHSPC patients only, also no ttCRPC or OS differences were observed for ARPI vs. docetaxel (all p > 0.05). Regarding sequential therapies, no PFS and OS differences were observed for all and specifically high volume mHSPC patients, when ARPI-ARPI vs. ARPI-docetaxel vs. docetaxel-ARPI treatments were compared (all p > 0.05).

Conclusion: In real-world setting, ARPI treatment performs comparable to docetaxel chemotherapy in mHSPC. Therefore, docetaxel should only be used in triplet therapy. Moreover, no differences for sequential therapies of ARPI/docetaxel combinations in first-line mCRPC were observed.

References

Lam B, Tsang V, Lee M, Chan K, Liu T, Ng B . A territory-wide real-world efficacy and toxicity analysis of abiraterone acetate versus docetaxel in 574 Asian patients with metastatic hormone-sensitive prostate cancer. Clin Genitourin Cancer. 2023; 22(1):e75-e85.e1. DOI: 10.1016/j.clgc.2023.07.012. View

Ozaki K, Hatakeyama S, Narita S, Hata K, Yanagisawa T, Tanaka T . Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study. World J Urol. 2022; 41(1):67-75. DOI: 10.1007/s00345-022-04237-3. View

Armstrong A, Szmulewitz R, Petrylak D, Holzbeierlein J, Villers A, Azad A . ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2019; 37(32):2974-2986. PMC: 6839905. DOI: 10.1200/JCO.19.00799. View

Sydes M, Spears M, Mason M, Clarke N, Dearnaley D, de Bono J . Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol. 2018; 29(5):1235-1248. PMC: 5961425. DOI: 10.1093/annonc/mdy072. View

Wenzel M, Siech C, Hoeh B, Koll F, Humke C, Tilki D . Contemporary Treatment Patterns and Oncological Outcomes of Metastatic Hormone-sensitive Prostate Cancer and First- to Sixth- line Metastatic Castration-resistant Prostate Cancer Patients. Eur Urol Open Sci. 2024; 66:46-54. PMC: 11260326. DOI: 10.1016/j.euros.2024.06.010. View

Matsukawa A, Rajwa P, Kawada T, Bekku K, Laukhtina E, Klemm J . Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis. Int J Clin Oncol. 2024; 29(6):716-725. PMC: 11129990. DOI: 10.1007/s10147-024-02485-4. View

Hird A, Magee D, Cheung D, Matta R, Kulkarni G, Nam R . Abiraterone vs. docetaxel for metastatic hormone-sensitive prostate cancer: A microsimulation model. Can Urol Assoc J. 2020; 14(9):E418-E427. PMC: 7492043. DOI: 10.5489/cuaj.6234. View

Wenzel M, Cano Garcia C, Humke C, Hoeh B, Steuber T, Tilki D . Prostate-specific Antigen Nadir and Cancer-Control Outcomes in Real-world Apalutamide-treated Metastatic Hormone-Sensitive Prostate Cancer Patients: A Single-Center Analysis. Eur Urol Oncol. 2024; . DOI: 10.1016/j.euo.2024.08.007. View

Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev B . Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017; 377(4):352-360. DOI: 10.1056/NEJMoa1704174. View

10.

Mandel P, Hoeh B, Wenzel M, Preisser F, Tian Z, Tilki D . Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis. Eur Urol Focus. 2022; 9(1):96-105. DOI: 10.1016/j.euf.2022.08.007. View

11.

Kyriakopoulos C, Chen Y, Carducci M, Liu G, Jarrard D, Hahn N . Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018; 36(11):1080-1087. PMC: 5891129. DOI: 10.1200/JCO.2017.75.3657. View

12.

Davis I, Martin A, Stockler M, Begbie S, Chi K, Chowdhury S . Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019; 381(2):121-131. DOI: 10.1056/NEJMoa1903835. View

13.

Yanagisawa T, Rajwa P, Thibault C, Gandaglia G, Mori K, Kawada T . Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2022; 82(6):584-598. DOI: 10.1016/j.eururo.2022.08.002. View

14.

Tsaur I, Heidegger I, Bektic J, Kafka M, van den Bergh R, Hunting J . A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer. Cancer Med. 2021; 10(18):6354-6364. PMC: 8446402. DOI: 10.1002/cam4.4184. View

15.

Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Flechon A . Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022; 399(10336):1695-1707. DOI: 10.1016/S0140-6736(22)00367-1. View

16.

Hoeh B, Garcia C, Wenzel M, Tian Z, Tilki D, Steuber T . Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume. Eur Urol Focus. 2023; 9(5):838-842. DOI: 10.1016/j.euf.2023.03.024. View

17.

Wenzel M, Wurnschimmel C, Nocera L, Colla Ruvolo C, Tian Z, Shariat S . Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis. Eur Urol Focus. 2021; 8(2):399-408. DOI: 10.1016/j.euf.2021.04.003. View

18.

Roy S, Sayyid R, Saad F, Sun Y, Lajkosz K, Ong M . Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis. Eur Urol Oncol. 2022; 5(5):494-502. DOI: 10.1016/j.euo.2022.06.003. View

19.

Preisser F, Chun F, Banek S, Wenzel M, Graefen M, Steuber T . Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer. Prostate Int. 2021; 9(3):113-118. PMC: 8498729. DOI: 10.1016/j.prnil.2020.12.003. View

20.

Chi K, Agarwal N, Bjartell A, Chung B, Pereira de Santana Gomes A, Given R . Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2019; 381(1):13-24. DOI: 10.1056/NEJMoa1903307. View